Lyell Wealth Management LP lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 46.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,413 shares of the biopharmaceutical company’s stock after selling 19,955 shares during the period. Lyell Wealth Management LP’s holdings in Pfizer were worth $1,014,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. BKD Wealth Advisors LLC raised its holdings in Pfizer by 2.5% in the 4th quarter. BKD Wealth Advisors LLC now owns 104,315 shares of the biopharmaceutical company’s stock worth $4,553,000 after purchasing an additional 2,561 shares during the period. Strs Ohio raised its holdings in Pfizer by 1.5% in the 4th quarter. Strs Ohio now owns 2,996,080 shares of the biopharmaceutical company’s stock worth $130,778,000 after purchasing an additional 45,159 shares during the period. Suncoast Equity Management bought a new position in Pfizer in the 4th quarter worth $256,000. Winslow Evans & Crocker Inc. raised its holdings in Pfizer by 44.2% in the 4th quarter. Winslow Evans & Crocker Inc. now owns 62,336 shares of the biopharmaceutical company’s stock worth $2,722,000 after purchasing an additional 19,122 shares during the period. Finally, First National Bank of Omaha raised its holdings in Pfizer by 0.8% in the 4th quarter. First National Bank of Omaha now owns 294,415 shares of the biopharmaceutical company’s stock worth $12,851,000 after purchasing an additional 2,397 shares during the period. Institutional investors own 71.81% of the company’s stock.
NYSE:PFE traded up $0.17 on Friday, reaching $34.65. 28,267,400 shares of the company’s stock traded hands, compared to its average volume of 34,506,988. The company has a quick ratio of 1.27, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. The stock has a 50-day simple moving average of $40.84 and a 200-day simple moving average of $41.69. The firm has a market cap of $190.71 billion, a PE ratio of 11.55, a P/E/G ratio of 2.75 and a beta of 0.63. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 4.16%. Pfizer’s dividend payout ratio is presently 48.00%.
A number of equities analysts recently commented on the company. UBS Group reaffirmed a “neutral” rating and issued a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Morgan Stanley cut Pfizer from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $48.00 to $40.00 in a report on Tuesday, July 30th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Barclays reaffirmed a “hold” rating and issued a $41.00 target price on shares of Pfizer in a report on Thursday, May 9th. Finally, JPMorgan Chase & Co. set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Fourteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $46.56.
In other Pfizer news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares of the company’s stock, valued at $21,588,536.23. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $44.00, for a total value of $1,320,000.00. Following the sale, the insider now directly owns 80,094 shares in the company, valued at $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is owned by company insiders.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.